Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any hypertrophic cardiomyopathy in which the cause of the disease is a mutation in the CSRP3 gene.
Features include always present findings: Thickened heart muscle (hypertrophic cardiomyopathy); and common findings: Reduced left ventricular endsystolic diameter and Thickened wall between heart chambers (ventricular septal hypertrophy). 6 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Heart and blood vessels | 6 | Reduced left ventricular endsystolic diameter, Thickened heart muscle (hypertrophic cardiomyopathy), Thickened wall between heart chambers (ventricular septal hypertrophy) |
CSRP3 encodes cysteine and glycine rich protein 3 (194 aa). Positive regulator of myogenesis. Acts as a cofactor for myogenic bHLH transcription factors such as MYOD1, and probably MYOG and MYF6. Highest expression in Heart Left Ventricle (750.4 TPM) and Heart Atrial Appendage (603.9 TPM).
Hypertrophic cardiomyopathy 12 is associated with mutations in the CSRP3 gene on chromosome 11.
CSRP3 is classified as a druggable target (Transcription Factor category) with score 0.0.
Genetic testing for CSRP3 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for hypertrophic cardiomyopathy 12 has been reported in the published literature.
Phenotype severity distribution: 1 always present feature, 2 common features.
No clinical trials have been registered for hypertrophic cardiomyopathy 12.
299 publications have been identified in PubMed for hypertrophic cardiomyopathy 12. Research spans Epidemiology / Natural History (25%), Clinical Trial Publication (21%), and Review / Meta-Analysis (18%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 74 | 25% |
Data assembled from 5 of 12 sources · Last updated Sep 18, 2026, 9:13 PM UTC
Online Mendelian Inheritance in Man
Clinical study results
64 |
21% |
Research summaries | 53 | 18% |
Testing and diagnosis research | 44 | 15% |
Laboratory research | 36 | 12% |
Patient case studies | 12 | 4% |
New treatment approaches | 9 | 3% |
Other research | 7 | 2% |
Alabdaljabar MS (2026). [PMID: 41575418](https://pubmed.ncbi.nlm.nih.gov/41575418/). *JACC Clin Electrophysiol*. [Review / Meta-Analysis]
Dababneh SF (2026). [PMID: 41893039](https://pubmed.ncbi.nlm.nih.gov/41893039/). *J Pers Med*. [Epidemiology / Natural History]
Wu Z (2026). [PMID: 42087220](https://pubmed.ncbi.nlm.nih.gov/42087220/). *J Cardiothorac Surg*. [Clinical Trial Publication]
Zhu C (2026). [PMID: 40368289](https://pubmed.ncbi.nlm.nih.gov/40368289/). *Heart Rhythm*. [Epidemiology / Natural History]
Ibrahim M (2026). [PMID: 41641607](https://pubmed.ncbi.nlm.nih.gov/41641607/). *Crit Pathw Cardiol*. [Review / Meta-Analysis]
Nguyen O (2026). [PMID: 41837112](https://pubmed.ncbi.nlm.nih.gov/41837112/). *Card Fail Rev*. [Review / Meta-Analysis]
Badran HM (2026). [PMID: 42012930](https://pubmed.ncbi.nlm.nih.gov/42012930/). *Echocardiography*. [Epidemiology / Natural History]
Chaudhry WR (2026). [PMID: 41748278](https://pubmed.ncbi.nlm.nih.gov/41748278/). *Open Heart*. [Epidemiology / Natural History]
Fritzlen JT (2026). [PMID: 41546848](https://pubmed.ncbi.nlm.nih.gov/41546848/). *Curr Cardiol Rep*. [Review / Meta-Analysis]
Ozbay B (2026). [PMID: 41237829](https://pubmed.ncbi.nlm.nih.gov/41237829/). *Eur Heart J Cardiovasc Imaging*. [Clinical Trial Publication]